There’s no query Eli Lilly has been probably the most lively biopharma dealmaker of latest months, however even the billions the pharma already spent on acquisitions hasn’t exhausted its urge for food. The newest goal is California-based Engage Biologics, for which Lilly is paying $202 million. That quantity contains each an upfront payment and milestone…
Valneva is deliberate to shrink its headcount by up to 15% because the French vaccine developer continues to search methods to lower prices. The firm—whose vaccines embody the Japanese encephalitis shot Ixiaro and the cholera vaccine Dukoral—noticed first-quarter 2026 revenue drop to 30.9 million euros ($36.2 million) from 49.2 million euros ($57.6 million) for a…
pharmaceutical powerhouse Eli Lilly & Co. will buy Boston gene remedy maker Kelonia Therapeutics for not less than $3.25 billion, the businesses introduced Monday. The acquisition will grant Indianapolis-based Lilly entry to Kelonia’s blood most cancers therapy known as KLN-1010 that genetically modifies sufferers’ immune cells with out requiring them to be faraway from the…
